# Epoetin Alfa (EPO) in Subjects With Chronic Kidney Disease (CKD)

> **NCT00156962** · PHASE3 · TERMINATED · sponsor: **Amgen** · enrollment: 850 (estimated)

## Conditions studied

- Chronic Kidney Disease

## Interventions

- **DRUG:** Epoetin alfa DT
- **DRUG:** Epoetin alfa RB

## Key facts

- **NCT ID:** NCT00156962
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-04
- **Primary completion:** 2007-03
- **Final completion:** 2007-03
- **Target enrollment:** 850 (ESTIMATED)
- **Why stopped:** Regulatory decision not to proceed
- **Last updated:** 2008-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00156962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00156962, "Epoetin Alfa (EPO) in Subjects With Chronic Kidney Disease (CKD)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00156962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*